FDA Introduces New Voucher and AI Initiatives to Accelerate Drug Approvals
TL;DR Summary
The FDA announced a new voucher program allowing companies supporting U.S. national interests to expedite their drug review process to one or two months, raising concerns about potential misuse and the influence of political criteria in fast-tracking approvals.
- Does the FDA commissioner’s new voucher program open a Pandora’s box? statnews.com
- FDA to offer faster drug reviews to companies promoting ‘national priorities’ AP News
- FDA launches new priority review voucher program for biopharmas that ‘align with national priorities’ Fierce Biotech
- F.D.A. to Use A.I. in Drug Approvals to ‘Radically Increase Efficiency’ The New York Times
- US FDA to shorten review time for drug developers under new voucher program Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
1 min
vs 2 min read
Condensed
84%
245 → 38 words
Want the full story? Read the original article
Read on statnews.com